E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Symptoms of Depression as defined by the Hospital Anxiety and Depression Questionnaire associated with Rheumatoid Arthritis |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the effects of Venlaflaxine in a rheumatoid population who have evidence of symptoms of depression |
|
E.2.2 | Secondary objectives of the trial |
To observe the effect treating depression has on an individuals physical activity as measured with a 24 hour ambulatory activity monitor |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
Rheumatoid Arthritis(ACR criteria) Male or Female Aged 18 years or over. Female patients of childbearing potential must be using an adequate and reliable method of contraception whilst taking Venlaflaxine. Willing and able to provide written informed consent. Functional classification of II or III (ACR criteria) A score > 10 on the Hospital anxiety and Depression score
|
|
E.4 | Principal exclusion criteria |
Previously Diagnosed Depression Other physically disabling condition/concomitant chronic disease Contraindicated use of Venlaflaxine
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Depression is very common in RA, yet assessment and treatment is not routine practice. In a recent survey in our department, depression, as indicated by the HAD >8 score, was found in 45% of 123 participants, with 25% (HAD >10) categorised as either moderately or severely depressed. Primary treatment of RA is aimed at reducing inflammation and improving function. Part of this function is ambulation which can be objectively measured using a specifically designed monitor, the NUMACT. Reduced physical function is also considered to be a feature of depression and therefore it is anticipated that an improvement in mental health may also contribute to improved physical function.
This is an intervention study using a licensed antidepressant treatment (Venlaflaxine) in patients with diagnosed rheumatoid arthritis. The aim is to observe changes in mental state as defined by the HAD score and physical activity as measured by the Numact ambulatory activity monitor. The secondary aim is to observe changes in self-report disability (HAQ), depression and anxiety (HAD), pain and fatigue (VAS P/F) scores and a multi-dimensional health status questionnaire (SF36). HAQ - Health Assessment Questionnaire (Fries, et al 1980) HAD - Hospital Anxiety and Depression (Zigmond & Snaith, 1983) VAS P/F - Visual analogue scale Pain / Fatigue (McCormack et al 1988) SF36 - Short Form 36
This is an open, observational PILOT study of 20 patients with diagnosed rheumatoid arthritis who are indicating symptoms of depression; and therefore no sample size has been calculated.
It is an un-controlled, open label pilot study to test the effect of treating depression associated with rheumatoid arthritis (RA) using Venlaflaxine. All suitable patients will be given an information sheet and a consent form in the outpatient clinic explaining the nature of the study and the risks and benefits involved and they will be made aware that their inclusion is entirely voluntary and their decision will bear no effect on future treatment or relationships with their physician or health carers.
The patients will be purposefully recruited, via routine outpatient clinic appointments, and based upon a clinical need for antidepressant therapy, determined by the treating physician. There will be a contact telephone number to reach the researcher should they wish to proceed. If the patient has indicated a need for such treatment but has declined to take part in the study then advice will be given to contact their GP in relation to potential therapy.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial is the last visit, of the last subject, recruited into the study. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |